Complications at inclusion of the patients and newly developed complications in the intent to treat analysis
| Number of patients with complications at inclusion (n=302) | Number of patients with newly developed complications | ||||
|---|---|---|---|---|---|
| Placebo (n=103) | O1 (n=98) | O2 (n=101) | |||
| Local and organ complications | |||||
| Shock | 42 | 8 | 2 | 4 | |
| Sepsis | 14 | 4 | 4 | 5 | |
| Pulmonary failure | 98 | 20 | 13 | 17 | |
| Renal insufficiency | 25 | 5 | 7 | 5 | |
| Peritonitis | 13 | 2 | 1 | 7 | |
| Haemorrhage | 4 | 7 | 3 | 4 | |
| Abscess/infected pancreatic necrosis | 6 | 8 | 8 | 7 | |
| Fluid collection | 144 | 7 | 3 | 5 | |
| Ileus/subileus | 281 | 2 | 1 | 0 | |
| Metabolic complications | |||||
| Hypocalcaemia | 108 | 32 | 31 | 26 | |
| Coagulopathy | 58 | 34 | 32 | 26 | |
| Hyperglycaemia | 191 | 14 | 15 | 18 | |
| Metabolic acidosis | 55 | 11 | 11 | 10 | |
| Jaundice | 167 | 15 | 14 | 19 | |
| Encephalopathy | 20 | 3 | 2 | 9 | |
| Death | 43 | 16 | 15 | 12 | |